Oculis Holding (OCS) Price & Analysis

Compare

94 Followers

OCS Stock Chart & Stats

$18.91

$0.20(1.10%)

At close: Jan 08 4:00 PM EST

$18.91

$0.20(1.10%)

Day’s Range― - ―

52-Week Range$14.00 - $23.08

Previous CloseN/A

Volume95.89K

Average Volume (3M)58.01K

Market Cap

$1.05B

Enterprise Value$814.84M

Total Cash (Recent Filing)$46.44M

Total Debt (Recent Filing)$2.47M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Mar 23, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding54,533,672

10 Day Avg. Volume127,612

30 Day Avg. Volume58,014

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)8.50

Price to Sales (P/S)908.96

P/FCF Ratio-13.06

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue1.62K

Enterprise Value/Gross Profit-56.57

Enterprise Value/Ebitda-7.91

Forecast

1Y Price Target

$39.50

Price Target Upside108.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company has reported pro-forma cash of $292 million, which is expected to provide financial stability until 2029.

Market OpportunityThe PIONEER registrational program targets an untapped market opportunity of over $7 billion.

Regulatory ProgressUpcoming results from phase 3 trials are anticipated to support a New Drug Application filing, indicating potential regulatory approval.

Bears Say

Trial DelaysData from the announced PIONEER phase 3 trials for OCS-05 are unlikely to deliver results until 2028.

Oculis Holding News

Oculis price target lowered to $29 from $30 at BofA

BofA lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating...

17d ago

OCS

3 Best Stocks to Buy Now, 11/11/2025, According to Top Analysts

If you’re on the hunt for promising opportunities, these three stocks have recently drawn Strong Buy ratings from...

19d ago

OCS

ACHR

Oculis price target raised to $42 from $36 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $42 from $36 and...

19d ago

OCS

Oculis files to sell 494K ordinary shares for holders

16:50 EST Oculis (OCS) files to sell 494K ordinary shares for holders Published first on TheFly – the...

19d ago

OCS

Oculis reports Q3 EPS (32c), consensus (41c)

Riad Sherif, Chief Executive Officer of Oculis (OCS), stated: “Oculis has entered a pivotal stage in its transformation...

19d ago

OCS

Oculis Holding: Promising Pipeline Developments and Strong Financial Position Support Buy Rating

Analyst Serge Belanger from Needham maintained a Buy rating on Oculis Holding and keeping the price target at...

19d ago

OCS

Oculis Holding AG Reports Q3 2025 Financial Progress

Oculis Holding Ag ( ($OCS) ) has released its Q3 earnings. Here is a breakdown of the information...

19d ago

OCS

Oculis Holding AG Reports Q3 2025 Financial Results

An update from Oculis Holding ( ($OCS) ) is now available. On November 10, 2025, Oculis Holding AG...

20d ago

OCS

OCS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Oculis Holding Ag (OCS) is scheduled to report 3rd quarter earnings on 11/10/2025. Regarding Q3 estimates, Wall Street...

22d ago

OCS

Oculis Holding AG Secures $110 Million in Oversubscribed Share Offering

The latest update is out from Oculis Holding ( ($OCS) ). On October 29, 2025, Oculis Holding AG...

30d ago

OCS

Oculis Holding AG Suspends $100 Million Share Sale Agreement

An announcement from Oculis Holding ( ($OCS) ) is now available. On October 29, 2025, Oculis Holding AG...

1M ago

OCS

Oculis price target raised to $51 from $33 at Chardan

Chardan raised the firm’s price target on Oculis (OCS) to $51 from $33 and keeps a Buy rating...

2M ago

OCS

Oculis price target raised to $30 from $28 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Oculis (OCS) to $30 from $28 and keeps...

2M ago

OCS

Oculis price target raised to $36 from $33 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $36 from $33 and...

2M ago

OCS

OCS FAQ

What was Oculis Holding’s price range in the past 12 months?

Oculis Holding lowest stock price was $14.00 and its highest was $23.08 in the past 12 months.

What is Oculis Holding’s market cap?

Oculis Holding’s market cap is $1.05B.

When is Oculis Holding’s upcoming earnings report date?

Oculis Holding’s upcoming earnings report date is Mar 23, 2026 which is in 113 days.

How were Oculis Holding’s earnings last quarter?

Oculis Holding released its earnings results on Nov 10, 2025. The company reported -$0.402 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.119.

Is Oculis Holding overvalued?

According to Wall Street analysts Oculis Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding pay dividends?

Oculis Holding does not currently pay dividends.

What is Oculis Holding’s EPS estimate?

Oculis Holding’s EPS estimate is -0.52.

How many shares outstanding does Oculis Holding have?

Oculis Holding has 54,533,672 shares outstanding.

What happened to Oculis Holding’s price movement after its last earnings report?

Oculis Holding reported an EPS of -$0.402 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went down -0.103%.

Which hedge fund is a major shareholder of Oculis Holding?

Currently, no hedge funds are holding shares in OCS

Oculis Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

-80.98%

Trailing 12-Months

Asset Growth

47.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding (OCS) Earnings & Revenues

Historic Earnings Reports

OCS Stock 12 Month Forecast

Average Price Target

$39.50

▲(108.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","31":"$31","52":"$52","20.5":"$20.5","41.5":"$41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.5,31,41.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.28,21.720000000000002,24.16,26.6,29.04,31.48,33.92,36.36,38.8,41.24,43.68,46.120000000000005,48.56,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.28,20.835384615384616,22.39076923076923,23.946153846153848,25.501538461538463,27.056923076923077,28.612307692307695,30.16769230769231,31.723076923076924,33.27846153846154,34.83384615384615,36.38923076923077,37.94461538461539,{"y":39.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.28,20.02769230769231,20.775384615384617,21.523076923076925,22.270769230769233,23.01846153846154,23.76615384615385,24.513846153846153,25.261538461538464,26.00923076923077,26.75692307692308,27.504615384615384,28.252307692307692,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >